Target
LAG3
17 abstracts
Abstract
Spatial patterns in the tumor immune microenvironment as prognostic and predictive biomarkers of panitumumab (Pmab), fluorouracil and folinic acid (FU/FA) or FU/FA maintenance therapy following Pmab+FOLFOX induction in RAS wildtype (wt) metastatic colorectal cancer (mCRC): PanaMa (AIO KRK0212) trial.Org: Munich Hospital Neuperlach, Dr Hancken Hospital, DKTK, German Cancer Research Centre (DKFZ), University Hospital, LMU Munich,
Abstract
A signal-finding study of nivolumab and relatlimab in patients with advanced chordoma.Org: Division of Hematology and Oncology, UCLA Department of Medicine, Los Angeles, CA, Division of Hematology and Medical Oncology, Jonsson Comprehensive Cancer Center, University of California Los Angeles, Departments of Pediatrics and Orthopaedic Surgery, David Geffen School of Medicine, University of California Los Angeles, Cumming School of Medicine, Department of Surgery, Orthopedic Surgery, Calgary, Department of Orthopedic Surgery, UCLA,
Abstract
A phase 2 study to determine the pathological (path) response to neoadjuvant nivolumab (nivo) and relatlimab (rela) in stage I to III resectable Merkel cell carcinoma (Neo-MCC).Org: Melanoma Institute Australia,
Abstract
Characterization of the immunophenotype and tumor specificity of CD8+ T-cells in chromophobe renal cell carcinoma (ChRCC) and renal oncocytic neoplasms.Org: Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, St. Elizabeth's Medical Center, Brighton, MA,
Abstract
Pan-cancer analysis of natural killer (NK) cell infiltration in human malignancies: Molecular features and clinical implications.Org: Caris Life Sciences, Irving, TX, Barbara Ann Karmanos Cancer Institute, St. John's Cancer Institute, Santa Monica, CA, Brown University - Lifespan Cancer Institute, University of Minnesota Masonic Cancer Center, Minneapolis, MN,
Abstract
Comparison of immune microenvironment between primary and metastatic breast tumors.Org: Labcorp Oncology, Duke University Medical Center, Duke Cancer Institute, Department of Pathology, Durham, NC, OmniSeq (Labcorp), Roswell Park Comprehensive Cancer Center, OmniSeq, Inc., Personal Genome Diagnostics (Labcorp),
Abstract
Comprehensive characterization of androgen receptor expression in breast cancer.Org: Caris Life Sciences, Irving, TX, City of Hope National Medical Center, Washington University School of Medicine in St Louis, Lifespan Cancer Institute, The Warren Alpert Medical School of Brown University, Providence, RI,
Abstract
Pan-cancer analysis of IDO1 transcriptome expression and its impact on outcome in patients treated with immune checkpoint inhibitors.Org: OmniSeq (Labcorp), OmniSeq Inc. (Labcorp),
Abstract
Circulating tumor DNA of classical Hodgkin lymphoma.Org: Institute of Oncology Research, Aou Federico II, AO S.Croce e Carle, Clinical and Experimental Onco Hematology Unit, Medical University of Gdansk,
Abstract
Effect of a novel expansion process on tumor-infiltrating lymphocyte (TIL) polyfunctionality, cytotoxicity, and expansion, while preserving cells in a less differentiated and more stem-like phenotype.Org: Iovance Biotherapeutics,
Abstract
Phase Ib/II study of XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) combination in metastatic melanoma refractory to prior immune checkpoint inhibitor therapy with and without CNS disease.Org: UCSF Hem/Onc Fellowship, University of California-San Francisco,
Abstract
A phase 2 study to determine the pathological (path) response to neoadjuvant nivolumab (nivo) and relatlimab (rela) in high-risk stage II cutaneous melanoma: NeoReNi II.Org: Melanoma Institute Australia, Royal Prince Alfred Hospital, Camperdown, NSW, Australia, Chris O'Brien Lifehouse, The University of Sydney, The Mater Hospital Sydney,
Abstract
Exploring the potential of combination immune checkpoint strategies in non-small cell lung cancer (NSCLC).Org: Mayo Clinic, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, University of Alabama at Birmingham Department of Hematology, Birmingham, AL, University of Alabama-Birmingham,
Abstract
Safety, tolerability, and pharmacokinetics of HLX26 (an anti-LAG3 antibody) in patients with advanced or metastatic solid tumors or lymphomas.Org: Fudan University Shanghai Cancer Center, Shanghai Henlius Biotech, Inc.,
Abstract
Implications of GITR expression profile for precision immunotherapeutics.Org: Moores Cancer Center, UC San Diego Health, Medical College of Wisconsin and WIN Consortium, Dartmouth Cancer Center, Lebanon, NH, OmniSeq (Labcorp), OmniSeq Inc. (Labcorp),
Abstract
TIGIT transcriptomic expression and high levels of multiple checkpoints across diverse cancers.Org: OmniSeq (Labcorp), Labcorp Oncology , OmniSeq Inc. (Labcorp), Medical College of Wisconsin and WIN Consortium,
Abstract
Real-world experience of tebentafusp for uveal melanoma via an Australian access program.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Peter MacCallum Cancer Centre, Melbourne, Australia, Melbourne, Australia, The Kinghorn Cancer Centre, Darlinghurst, Australia,